2020-04-16
A biotechnology company developing next-generation vaccines for serious infectious diseases, announced it has identified a coronavirus vaccine candidate, a stable, prefusion protein made using proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May.
